Advertisement
U.S. markets closed

CareDx, Inc (CDNA)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
8.270.00 (0.00%)
At close: 04:00PM EST
8.20 -0.07 (-0.85%)
After hours: 08:00PM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
MACD

MACD

Previous Close8.27
Open8.27
Bid8.24 x 800
Ask8.23 x 1000
Day's Range8.08 - 8.44
52 Week Range4.80 - 17.89
Volume356,237
Avg. Volume1,063,404
Market Cap447.394M
Beta (5Y Monthly)1.38
PE Ratio (TTM)N/A
EPS (TTM)-1.69
Earnings DateFeb 28, 2024
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est12.40
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for CDNA

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • CareDx, Inc.
    Analyst Report: Thermo Fisher Scientific Inc.Thermo Fisher Scientific sells scientific instruments and laboratory equipment, diagnostics consumables, and life science reagents. The firm operates through four segments (revenue figures include some cross-segment revenue): analytical technologies (16% of sales); specialty diagnostic products (17%); life science solutions (38%); and lab products and services (38%).
    Rating
    Fair Value
    Economic Moat
    3 years agoMorningstar
View more
  • Business Wire

    CareDx to Report Fourth Quarter and Full Year 2023 Financial Results

    BRISBANE, Calif., February 21, 2024--CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced it will report financial results for the fourth quarter and full year 2023 after market close on Wednesday, February 28, 2024. Company management will host a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:3

  • Business Wire

    CareDx Showcases Digital Solutions and Pipeline in Cellular Transplant and Therapy Monitoring at the 2024 Tandem Meetings

    BRISBANE, Calif., February 21, 2024--CareDx, Inc. (Nasdaq: CDNA) —The Transplant Company™ — a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers — today announced that it will be showcasing the breadth of its specialized digital solutions and the latest advancements in its cellular therapy and transplant monitoring pipeline at the 2024 Tandem Meetings,

  • Business Wire

    CareDx Issues Statement in Patent Infringement Case

    BRISBANE, Calif., January 27, 2024--CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced the jury verdict in the patent litigation brought by Natera, Inc. (Nasdaq: NTRA).